Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BAMF (Biomarker Amplification Filter) shows promise for early MS (multiple sclerosis) diagnostic:

This article was originally published in Clinica

Executive Summary

Eclipse Diagnostics, a subsidiary of Large Scale Biology (LSB), says that evidence shows that its BAMF technology (Biomarker Amplification Filter) could lead to early diagnosis of multiple sclerosis (MS) and other life-threatening diseases. In a presentation last week at the American Academy of Neurology Meeting, in San Francisco, California, researchers using the BAMF technology reported the presence of distinct proteomic signatures in blood serum from MS patients. According to Vacaville, California-based LSB, findings from the study, entitled, "A Blood Test to Diagnose Multiple Sclerosis: Use of MALDI/TOF and Serum Proteomic Pattern Analysis", provide "further confirmation that the BAMF technology will lead to early diagnosis of diseases such as multiple sclerosis and various cancers."





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts